In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography

Neurobiology of Aging

Volumn 34, Issue 7, 2013, Pages 1790-1798

  Rojas, Santiago ^a   Herance, José Raúl ^a   Gispert, Juan Domingo ^b,c   Abad, Sergio ^a   Torrent, Élia ^a   Jiménez, Xavier ^a   Pareto, Deborah ^d   Perpiña, Unai ^e   Sarroca, Sara ^e   Rodríguez, Elisenda ^e   Ortega Aznar, Arantxa ^d   Sanfeliu, Coral ^e  

^a CRC Centre d'Imatge Molecular   (Spain)

^b Institut d'Alta Tecnologia   (Spain)

^c Hospital Universitari Vall d'Hebrón ^*  (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e INST D INVESTIGACIONS B   (Spain)

Author keywords

11C PIB; 18F FDG; 18F Florbetapir; Alzheimer's disease; Amyloid plaque; Mice; PET

Indexed keywords

AMYLOID; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; 2 (4' (METHYLAMINO)PHENYL) 6 HYDROXYBENZOTHIAZOLE; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; GLUCOSE; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DIAGNOSTIC IMAGING EQUIPMENT; DRUG UPTAKE; GLUCOSE INTAKE; GLUCOSE METABOLISM; IN VIVO STUDY; MOUSE; NEUROPATHOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRANSGENIC MOUSE; ANIMAL; BRAIN; EVALUATION STUDY; METABOLISM; METHODOLOGY; SCINTISCANNING; PROCEDURES;

AMYLOID; ANILINE COMPOUNDS; ANIMALS; BRAIN; FLUORODEOXYGLUCOSE F18; GLUCOSE; MICE; MICE, TRANSGENIC; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84875821298     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.12.027     Document Type: Article

References (34)

1. Barthel H., Gertz H.J., Dresel S., Peters O., Bartenstein P., Buerger K., Hiemeyer F., Wittemer-Rump S.M., Seibyl J., Reininger C., Sabri O. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011, 10:424-435. Florbetaben Study Group.
2. Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 2006, 355:2652-2663.
3. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P., Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 1997, 3:67-72.
4. Dubois A., Hérard A.S., Delatour B., Hantraye P., Bonvento G., Dhenain M., Delzescaux T. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuroimage 2010, 51:586-598.
5. Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. Neurol. Clin. 2007, 25:611-667.
6. Flood D.G., Lin Y.G., Lang D.M., Trusko S.P., Hirsch J.D., Savage M.J., Scott R.W., Howland D.S. Transgenic rat model of Alzheimer's disease with extracellular Abeta deposition. Neurobiol. Aging 2009, 30:1078-1090.
7. Franklin K., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, London.
8. Frisoni G.B. PET and 18F ligands in the diagnosis of Alzheimer's disease. Lancet Neurol. 2011, 10:397-399.
9. Herholz K., Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011, 10:667-670.
10. Herholz K., Westwood S., Haense C., Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J. Nucl. Med. 2011, 52:1218-1226.
11. Higgins L.S., Catalano R., Quon D., Cordell B. Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology. Ann. N. Y. Acad. Sci. 1993, 695:224-227.
12. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:137-143.
13. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
14. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25:10598-10606.
15. Kung M.P., Kung H.F. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl. Med. Biol. 2005, 32:673-678.
16. Kuntner C., Kesner A.L., Bauer M., Kremslehner R., Wanek T., Mandler M., Karch R., Stanek J., Wolf T., Müller M., Langer O. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. 2009, 11:236-240.
17. Luo F., Rustay N.R., Ebert U., Hradil V.P., Cole T.B., Llano D.A., Mudd S.R., Zhang Y., Fox G.B., Day M. Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol. Aging 2012, 33:933-944.
18. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., Suzuki K., Mori H., Higuchi M., Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27:10957-10968.
19. Manook A., Yousefi B.H., Willuweit A., Platzer S., Reder S., Voss A., Huisman M., Settles M., Neff F., Velden J., Schoor M., von der Kammer H., Wester H.J., Schwaiger M., Henriksen G., Drzezga A. Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One 2012, 7:e31310.
20. Mosconi L., Berti V., Glodzik L., Pupi A., De Santi S., de Leon M.J. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J. Alzheimers Dis. 2010, 20:843-854.
21. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26:10129-10140.
22. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
23. Poisnel G., Dhilly M., Moustié O., Delamare J., Abbas A., Guilloteau D., Barré L. PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol. Aging 2012, 33:2561-2571.
24. Poisnel G., Hérard A.S., El Tannir El Tayara N., Bourrin E., Volk A., Kober F., Delatour B., Delzescaux T., Debeir T., Rooney T., Benavides J., Hantraye P., Dhenain M. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol. Aging 2012, 33:1995-2005.
25. Reiman E.M., Uecker A., Gonzalez-Lima F., Minear D., Chen K., Callaway N.L., Berndt J.D., Games D. Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport 2000, 11:987-991.
26. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., Rodriguez Martinez de Liano S., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
27. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2002, 10:24-35.
28. Teng E., Kepe V., Frautschy S.A., Liu J., Satyamurthy N., Yang F., Chen P.P., Cole G.B., Jones M.R., Huang S.C., Flood D.G., Trusko S.P., Small G.W., Cole G.M., Barrio J.R. [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment. Neurobiol. Dis. 2011, 43:565-575.
29. Toyama H., Ye D., Ichise M., Liow J.S., Cai L., Jacobowitz D., Musachio J.L., Hong J., Crescenzo M., Tipre D., Lu J.Q., Zoghbi S., Vines D.C., Seidel J., Katada K., Green M.V., Pike V.W., Cohen R.M., Innis R.B. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:593-600.
30. Valla J., Chen K., Berndt J.D., Gonzalez-Lima F., Cherry S.R., Games D., Reiman E.M. Effects of image resolution on autoradiographic measurements of posterior cingulate activity in PDAPP mice: implications for functional brain imaging studies of transgenic mouse models of Alzheimer's Disease. Neuroimage 2002, 16:1-6.
31. Valla J., Gonzalez-Lima F., Reiman E.M. FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice. Int. J. Dev. Neurosci. 2008, 26:253-258.
32. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans G., Buckley C., Owenius R., Thurfjell L., Farrar G., Brooks D.J. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 2010, 68:319-329.
33. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., Dannals R.F., Nandi A., Brasić J.R., Ye W., Hilton J., Lyketsos C., Kung H.F., Joshi A.D., Skovronsky D.M., Pontecorvo M.J. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 2010, 51:913-920.
34. Woodruff-Pak D.S. Animal models of Alzheimer's disease: therapeutic implications. J. Alzheimers Dis. 2008, 15:507-521.